Bivalent mRNA COVID-19 vaccines were recommended for children and adolescents aged 5 to 17 years in the US, but were they effective? JAMA Associate Editor Tracy A. Lieu, MD, MPH, spoke with author Leora R. Feldstein, PhD, US Centers for Disease Control and Prevention, about the effectiveness of bivalent COVID-19 vaccines in children and adolescents.
Related Content:
Association of New-Onset Seizures With SARS-CoV-2 Vaccines
Measuring Medicaid Enrollment More Accurately to Guide Post–COVID-19 Pandemic Policy
February 2024 Medical News Summary
Changes in Access to Care and Preventive Services by Race and Ethnicity During the COVID-19 Pandemic
Safety and Effectiveness of Maternal and Child COVID-19 Vaccination
The Connection Between SARS-CoV-2 and Type 1 Diabetes Risk in Young Children
Efficacy of Gabapentin For Post–COVID-19 Olfactory Dysfunction
Innovative Approach to Promote Equitable Access to COVID-19 Preventive Therapy
How Safe Were Kids in School During Phases of the Pandemic?
Risk of New Retinal Vascular Occlusion After mRNA COVID-19 Vaccination
Use of Mental Health Services During the COVID-19 Pandemic
Use of Cardiopulmonary Exercise Testing to Evaluate Long COVID-19 Symptoms in Adults
Global COVID-19 Update
Receipt of Out-of-State Telemedicine Visits Among Medicare Beneficiaries During the COVID-19 Pandemic
Long COVID: The US Federal Response
Childcare Stress and Professional Outcomes Among US Health Care Workers During COVID-19
Global Association of COVID-19 Pandemic Measures With Cancer Screening
May 2022 Medical News Summary
Q&A With White House COVID-19 Response Coordinator Ashish Jha
Create your
podcast in
minutes
It is Free
JAMA Clinical Reviews
JAMA Editors’ Summary
JAMA Medical News
JAMAevidence The Rational Clinical Examination
JAMA Psychiatry Author Interviews